This effect might be linked to the activation of the Sirtuin 1—Peroxisome proliferator-activated receptor (PPAR)γ coactivator 1-alpha (SIRT1-PGC-1α)/NRF2 pathway, similar to the effects of aldose reductase inhibition in models of diabetic cardiomyopathy. Here, SIRT1 is linked to diabetic cardiomyopathy.